Taken together, our data above suggest that breast tumors, especially triple-negative and TP53-mutant breast tumors, show high levels of co-expression of genes implicated in centrosome amplification as well as genes implicated in centrosome clustering and that the coupling between these two mechanisms could engender poor outcomes in breast cancer patients. The gene discussed is TP53; the disease is breast carcinoma.